Collegium Pharmaceutical Projects 4% Revenue Growth for 2026, Refinances Debt for Significant Interest Savings
Summary
Collegium Pharmaceutical announced its 2026 financial guidance, projecting revenue growth driven by Jornay PM, and reported a significant debt refinancing that will lead to annualized interest savings and enhanced capital flexibility.
Key Events
-
2026 Financial Guidance Issued
The company projects full-year 2026 product revenues, net, in the range of $805 million to $825 million, representing a 4% increase from the 2025 midpoint. Jornay PM net revenue is expected to grow 32% to $190 million-$200 million, while adjusted EBITDA is guided to be flat at $455 million-$475 million.
-
Significant Debt Refinancing Completed
Collegium closed a $980 million syndicated credit facility, which was used to repay $581 million of its previous term loan, resulting in meaningful annualized interest savings.
-
Enhanced Capital Flexibility
The new credit facility includes a $300 million delayed draw term loan and a $100 million revolving credit facility, both currently undrawn, providing substantial capital for general corporate purposes and potential future business development opportunities.
-
Authorized Generic Agreement for Nucynta Products
The company entered into supply and quality agreements with Hikma Pharmaceuticals for authorized generic versions of Nucynta and Nucynta ER, with Collegium set to receive a significant share of net profits.
Analysis
This 8-K filing provides a positive outlook for Collegium Pharmaceutical, highlighting continued revenue growth, particularly from its ADHD treatment Jornay PM. The successful refinancing of a substantial portion of its debt at a reduced rate significantly strengthens the company's financial position by reducing interest expenses and providing considerable capital flexibility for future strategic initiatives. The authorized generic agreement for Nucynta products also helps to stabilize and diversify future revenue streams. While adjusted EBITDA is projected to remain flat despite revenue growth, the overall financial and strategic updates are favorable for the company's long-term stability and growth prospects.
At the time of this filing, COLL was trading at $47.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $23.23 to $50.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.